Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $1.0 million.

  • IDEAYA Biosciences' Other Non-Current Assets rose 2608.7% to $1.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 million, marking a year-over-year increase of 2608.7%. This contributed to the annual value of $1.0 million for FY2025, which is 2608.7% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported Other Non-Current Assets of $1.0 million as of Q4 2025, which was up 2608.7% from $805000.0 recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' Other Non-Current Assets registered a high of $1.0 million during Q4 2025, and its lowest value of $106000.0 during Q2 2022.
  • Its 5-year average for Other Non-Current Assets is $555250.0, with a median of $739500.0 in 2023.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 64622.64% in 2021, then plummeted by 8659.92% in 2022.
  • Quarter analysis of 5 years shows IDEAYA Biosciences' Other Non-Current Assets stood at $291000.0 in 2021, then plummeted by 63.57% to $106000.0 in 2022, then skyrocketed by 614.15% to $757000.0 in 2023, then rose by 6.34% to $805000.0 in 2024, then grew by 26.09% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q4 2025, $805000.0 for Q3 2025, and $805000.0 during Q2 2025.